US 11306149
Anti-CD40 antibodies and uses thereof
granted A61PA61P31/12A61P35/00
Quick answer
US patent 11306149 (Anti-CD40 antibodies and uses thereof) held by CytomX Therapeutics, Inc. expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61P, A61P31/12, A61P35/00